PMID- 31519572
OWN - NLM
STAT- MEDLINE
DCOM- 20190926
LR  - 20190926
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 39
IP  - 9
DP  - 2019 Sep
TI  - Amphiregulin/epiregulin mRNA Expression and Primary Tumor Location in Colorectal 
      Cancer.
PG  - 4729-4736
LID - 10.21873/anticanres.13655 [doi]
AB  - BACKGROUND/AIM: Amphiregulin (AREG) and epiregulin (EREG) mRNA expression levels 
      are predictors of response to anti-EGFR antibody therapy. Left-sided colon cancer 
      is more sensitive to anti-EGFR antibodies than right-sided, although the 
      mechanism is unclear. The aim of this study was to determine the relationship 
      between AREG, EREG mRNA expression levels and tumor location as well as the 
      efficacy of anti-EGFR antibody agents. MATERIALS AND METHODS: Real-time PCR was 
      used to assess AREG and EREG mRNA expression in metastatic colorectal cancer 
      (CRC) samples from 153 patients. RESULTS: Among KRAS(wt) samples, high AREG 
      expression (AREG(High)) was significantly more common in left-sided tumors than 
      in right-sided. Among patients who received anti-EGFR antibody, response rates 
      were significantly higher in AREG(High) than in AREG(Low) In the left-sided tumor 
      group, overall survival was significantly longer in patients with high EREG 
      levels than with low levels, whereas the right-sided tumor group showed no 
      survival difference between them. CONCLUSION: AREG and EREG mRNA expression 
      levels in left-sided CRC were higher than in right-sided tumors. This may help 
      explain why left-sided CRC is more responsive to anti-EGFR antibodies.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kuramochi, Hidekazu
AU  - Kuramochi H
AD  - Department of Chemotherapy, Yachiyo Medical Center, Tokyo Women's Medical 
      University, Chiba, Japan kuramochi.hidekazu@twmu.ac.jp.
FAU - Nakajima, G O
AU  - Nakajima GO
AD  - Department of Chemotherapy and Palliative Care, Tokyo Women's Medical University, 
      Tokyo, Japan.
FAU - Hayashi, Kazuhiko
AU  - Hayashi K
AD  - Department of Chemotherapy and Palliative Care, Tokyo Women's Medical University, 
      Tokyo, Japan.
FAU - Araida, Tatsuo
AU  - Araida T
AD  - Department of Surgery, Yachiyo Medical Center, Tokyo Women's Medical University, 
      Chiba, Japan.
FAU - Yamamoto, Masakazu
AU  - Yamamoto M
AD  - Department of Gastrointestinal Surgery, Tokyo Women's Medical University, Tokyo, 
      Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (AREG protein, human)
RN  - 0 (Amphiregulin)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Epiregulin)
RN  - 0 (RNA, Messenger)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amphiregulin/*genetics
MH  - Antineoplastic Agents, Immunological/pharmacology
MH  - Cell Line, Tumor
MH  - Colorectal Neoplasms/*genetics/mortality/pathology
MH  - Epiregulin/*genetics
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Organ Specificity/genetics
MH  - Prognosis
MH  - Proto-Oncogene Proteins p21(ras)/genetics
MH  - RNA, Messenger/*genetics
OTO - NOTNLM
OT  - Amphiregulin (AREG)
OT  - anti-EGFR antibody
OT  - colorectal cancer
OT  - epiregulin (EREG)
OT  - tumor location
EDAT- 2019/09/15 06:00
MHDA- 2019/09/27 06:00
CRDT- 2019/09/15 06:00
PHST- 2019/07/31 00:00 [received]
PHST- 2019/08/15 00:00 [revised]
PHST- 2019/08/16 00:00 [accepted]
PHST- 2019/09/15 06:00 [entrez]
PHST- 2019/09/15 06:00 [pubmed]
PHST- 2019/09/27 06:00 [medline]
AID - 39/9/4729 [pii]
AID - 10.21873/anticanres.13655 [doi]
PST - ppublish
SO  - Anticancer Res. 2019 Sep;39(9):4729-4736. doi: 10.21873/anticanres.13655.